MSMorten Scheibye-Knudsen

Morten Scheibye-Knudsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Morten Scheibye-Knudsen has a total of 922 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Upskilling in Healthy Longevity Medicine and Its Association With Physicians’ Implementation Intent and Self-Reported Clinical Confidence: Cross-Sectional Observational Study

    by Evelyne Bischof, Dominika Wilczok, James L Kirkland, Bhirau Wilaksono, Christine Yuan Huang, Suwanna Suwannaphong, Wanviput Sanphasitvong, Dalila Čamdžić, Carolina Hernandez, Yoko Madea, et al.

  • Open Access

    Precision geromedicine conference 2026 - Unlock Healthy Longevity nutraceuticals and repurposed drugs: Conference report

    by Duarte Barros, Wejdan M. Alenezi, Weilan Wang, Lihuan Guan, Nir Eynon, Morten Scheibye-Knudsen, Magali Moreau, Geng Zong, Vasso Apostolopoulos, Chen Huei Leo, et al.

    There is a growing demand from society for gerotherapeutic interventions that can extend healthspan. Yet the increasing commercialization of insufficiently validated gerotherapeutics threatens to undermine the public confidence and the responsible translation of healthy longevity research into practice. The Unlock Healthy Longevity Conference 2026 convened international experts in Singapore to exchange scientific advances in precision geromedicine, with a particular focus on nutraceuticals and repurposed drugs. Precision geromedicine is increasingly being translated into clinical settings; however, standardized frameworks for clinical evaluation, implementation, quality assurance, and oversight remain insufficiently established. This emerging paradigm emphasises the need for collaboration across multiple stakeholders to support the development of a robust, safe, scalable, and equitable ecosystem. A central theme across the sessions was the need to advance clinical human validation, translation, and the development of standards and clinical guidelines. Panel discussions converged on the importance of developing robust clinical and data infrastructures to generate reproducible evidence capable of informing real-world clinical practice and enable equitable access to healthy longevity. Presentations addressed emerging clinical biomarkers of ageing and data-driven approaches to guide gerotherapeutics, including changes in DNA methylation and skin and gut as organ-level readouts of biological ageing. Several potential candidate gerotherapeutics were discussed, including the nutraceutical compounds urolithin A and ergothioneine, and repurposed drugs such as glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Additional sessions explored the clinical implementation of gerotherapeutics taking into account ethical, safety, and regulatory considerations. This report summarises the key messages and research priorities presented at the conference.

  • Open Access

    The ectopic olfactory receptor OR10J5 counteracts skeletal muscle senescence and age-related decline

    by Yousin Suh, Ji-Sun Kim, Jiping Yang, Yena Lee, Subin Choi, Sung-Won Shin, Chaewon Hwang, Yeonho Lee, Sung-Yun Cho, HyeRim Han, et al.

    Skeletal muscle aging is characterized by a progressive decline in skeletal muscle mass and function, yet the molecular factors driving this deterioration remain incompletely understood. We identify the ectopic olfactory receptor OR10J5 as a regulator of skeletal muscle senescence and aging. Or10j5 mRNA expression is reduced across cellular models of senescence and muscle atrophy, mouse models of muscle atrophy, and naturally aged skeletal muscle. Genetic ablation of Or10j5 exacerbates age-associated muscle loss and functional decline in mice, accompanied by increased senescence-associated changes. Conversely, pharmacological activation of OR10J5 with lyral attenuates senescence- and atrophy-associated phenotypes and improves muscle mass and physical performance in naturally aged wild-type, but not Or10j5-deficient mice. Lyral similarly attenuates senescence- and atrophy-associated phenotypes in human embryonic stem cell-derived myotubes. Mechanistically, lyral activates OR10J5-dependent cAMP-PKA-CREB signaling and modulates transcriptional programs related to myogenesis, mitochondrial biogenesis, and cellular senescence. Together, these findings support OR10J5 activation as a potential strategy to counter age-related muscle decline.

  • Open Access

    Study protocol for FAXAge: a randomized, controlled clinical trial of fasting and exercise to slow aging in humans

    by Emma Bundgård Fals, Emilie Caroline Springborg, Adam Bjørnholdt Berthelsen, Jonas Nyeman-Nielsen, Steen Larsen, Morten Scheibye-Knudsen

    Biomarkers of aging, particularly DNA methylation-based clocks, have shown promise as tools to assess whether interventions may impact the rate of biological aging. Among possible interventions physical exercise has shown protective effects against many age-associated diseases, while time-restricted feeding (TRF) has shown metabolic benefits in preclinical models. The combined effect of exercise and TRF on aging biomarkers remains largely unexplored. In this 52-week four-armed, randomized, controlled trial (clinicaltrials.gov: NCT07207044) 240 healthy adults aged 65 and above will be allocated to four groups: combined cardio and strength training (EXE), TRF, combined EXE and TRF, or control. Participants will undergo assessments at baseline, 3, 6, and 12 months, with follow-ups at 2, 5, and 10 years. The primary outcome measure is Dunedin Pace of Aging DNA methylation age with secondary measures including RNA-sequencing, metabolomics, inflammatory markers, microbiome analysis, cognitive and physical measures. By deeply phenotyping participants, the Fasting And eXercise (FAXAge) study will provide novel insights into whether TRF, EXE, or a combination can slow or reverse biological aging in older adults.


  • Top Cited Papers
    Open Access

    The mitochondrial unfolded protein response in human microglia disrupts neuronal–glial communication and promotes senescence

    by Maria Jose Perez J, Alicia Lam, Christin Weissleder, Federico Bertoli, Hariam Raji, Mariella Bosch, Ivan Nemazanyy, Stefanie Kalb, Mohammed Kehili, Insa Hirschberg, et al.

    Mitochondria have evolved a specialized mitochondrial unfolded protein response (UPR mt ) to maintain proteostasis and promote recovery under stress. Studies in simple organisms have shown that UPR mt activation in glial cells supports proteostasis through beneficial non-cell-autonomous communication with neurons. However, the role of mitochondrial stress responses in the human brain remains unclear. To address this gap, we investigated the cell-type-specific effects of mitochondrial proteotoxic stress using human induced pluripotent stem cell-derived neuronal and glial cultures, as well as brain organoids. Here we show that mitochondrial proteotoxic stress induces metabolic rewiring in human microglia, marked by depletion of S-adenosylmethionine and lipid remodeling, ultimately leading to a senescent phenotype. Using human neuronal–glial tricultures and microglia-containing brain organoids, we identified the specific contributions of microglia to brain senescence and mitochondrial stress-driven neurodegenerative processes. UPR mt activation disrupts microglial communication with neighboring cells, triggering inflammatory signaling and impairing proteostasis. Together, these findings reveal how impaired mitochondrial proteostasis alters intercellular networks and identify a critical role for the UPR mt in neurodegenerative disease pathogenesis.


  • Open Access

    Cardiac FGF21 acts as an endocrine suppressor of female fertility in mitochondrial cardiomyopathy

    by Eric Verdin, Olga Bielska, Wendy Jara, Prasanna Kumaar, Génesis Vega Hormazabal, Bikem Soygur, Anne Marker, Ritesh Tiwari, Navreet Raj, Indra Heckenbach, et al.

    Cardiomyopathy is clinically associated with female infertility, yet whether the failing heart directly suppresses reproduction has remained unknown. Here we identify a heart–brain endocrine axis in which pathological cardiac stress induces systemic elevation of the mitokine FGF21, which in turn suppresses the hypothalamic-pituitary-gonadal axis and inhibits fertility. In female mice with dilated cardiomyopathy caused by mitochondrial fission deficiency (Mff KO), we observe delayed puberty, anovulation, and hypogonadotropic hypogonadism due to blunted LH secretion and selective suppression of hypothalamic kisspeptin neurons. Exogenous kisspeptin administration restores ovulation despite persistent cardiac dysfunction. Integrated transcriptomics and metabolomics analyses reveal that the signal originates from a cardiac mitochondrial integrated stress response that drives de novo FGF21 expression in the heart. Cardiac-specific Mff re-expression abolishes the signal at its source, while genetic deletion of Fgf21 fully restores puberty and fertility even in the presence of ongoing cardiomyopathy. These findings demonstrate that cardiac-derived FGF21 acts as a key endocrine suppressor of the reproductive axis during heart failure, revealing an inter-organ communication pathway that links cardiac mitochondrial stress to reproductive control.

  • Connecting fragmented aging research through the European Federation for Aging Research

    by Björn Schumacher, Morten Scheibye-Knudsen, Lene Juel Rasmussen, Folkert Kuipers


  • Top Cited Papers

    Target identification and assessment in the era of AI

    by Frank W. Pun, Dmitriy Podolskiy, Evgeny Izumchenko, Andrew Mortlock, Tudor I. Oprea, Morten Scheibye-Knudsen, Kristen Fortney, Eric Morgen, Feng Ren, Alex Zhavoronkov

    Drug discovery and development is time-intensive, expensive and laden with risk. Identifying the right drug targets is crucial for increasing the probability of success, but traditional target identification and validation often take years, and a target is only fully validated once a drug based on it receives approval by regulatory agencies. Given its proficiency in analysing large datasets and intricate biological networks, artificial intelligence (AI) is playing an increasingly important role in drug target identification and assessment. This article reviews recent advances in target discovery, emphasizing key considerations in target selection and breakthroughs in the application of AI-driven approaches for therapeutic target exploration, as well as challenges and limitations. We also highlight examples where AI tools have enabled or supported the identification of targets for which drug candidates have entered clinical trials.


  • Top Cited Papers
    Open Access

    p21+TREM2+ senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease

    by Ivan A. Salladay-Perez, Itzetl Avila, Lizeth Estrada, Andreea C. Alexandru, Cristian Ponce, Anika Dhingra, Grasiela Torres, Christina Y. Deng, Ronak Hegde, Julia Gensheimer, et al.

    Cellular senescence drives chronic sterile inflammation during aging via the senescence-associated secretory phenotype, yet the senescent cell types responsible are poorly defined. Macrophages share multiple features of senescence, including inflammatory secretion, yet whether macrophages can adopt a senescent state remains unclear. Here we identify p21⁺Trem2⁺ senescent macrophages as a major source of inflammaging, using primary mouse and human macrophage models of DNA damage and cholesterol-induced senescence characterized by multi-omic profiling. We found that senescent macrophages exhibit a distinctive p21-TREM2 expression profile and senescence-associated secretory phenotype, driven in part by type I interferon signaling via cytosolic mitochondrial DNA. We also found that senescent macrophage accumulation occurs in aging, metabolic dysfunction-associated steatotic liver disease mouse livers, and is enriched in human cirrhotic liver tissue. Finally, senolytic treatment targeting senescent macrophages reduced liver inflammation and steatosis in both aged mice and mice with metabolic dysfunction-associated steatotic liver disease. These findings establish macrophage senescence as a central driver of chronic inflammation in aging and metabolic liver disease, and a tractable therapeutic target.


  • Open Access

    Chronic Kidney Disease and Cellular Senescence

    by Marya Morevati, Juliette Tavenier, Morten Scheibye-Knudsen, Morten Baltzer Houlind, Aram Hedayati, Mads Hornum

    Chronic kidney disease (CKD) and kidney aging share many pathological and molecular features, with cellular senescence emerging as a potentially important contributor to disease progression. Senescent cells accumulate in the kidneys due to persistent stressors, contributing to chronic inflammation and fibrosis via the senescence-associated secretory phenotype (SASP). This review explores the intersection between CKD and renal aging, focusing on the mechanisms driving senescence, its impact on kidney function, and potential therapeutic interventions. We explore various senotherapeutic approaches, such as senolytics, senomorphics, and rejuvenating agents, and highlight the increasing role of artificial intelligence (AI) and machine learning (ML) in detecting and monitoring senescent cells, enabling high-throughput and precise assessment across experimental and clinical settings. Understanding these mechanisms offers new avenues for developing targeted treatments to slow CKD progression and improve patient outcomes.